Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GSK Announces New Beijing R&D Center for Infectious Diseases

publication date: Mar 30, 2016
GlaxoSmithKline will create a new R&D institute in Beijing that will address the public health threats of infectious disease and antibiotic resistance. GSK will budget $29 million for the project over the next three years and put over 20 researchers to work on the program. In GSK's vision, the project will start with its own R&D ability, while actively seeking participation from China academics, government, healthcare providers and regulators. The new research effort will be in addition to GSK's existing R&D efforts in Shanghai. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China